Mitralign, Inc., a near Boston, Massachusetts, USA-based valve repair company, raised $39.8m in Series E equity funding.
The backers were not disclosed.
Led by Rick Geoffrion, chief executive officer, Mitralign develops direct transcatheter mitral and tricuspid valve repair solutions.
The company intends to use the funds to continue growing its platform by pursuing US and CE regulatory approval for the commercialization of their Trialign system in parallel with preparations for commercial launch in Europe of their Mitralign Percutaneous Annuloplasty System (MPAS).
Both the Trialign and MPAS Systems feature a customizable therapy solution in concert with an extremely small presence, which leaves all clinical options open for the physician, a key consideration for a front line intervention.
The Trialign System is currently enrolling patients in an early feasibility IDE study in the US and is not approved for sale or distribution.
The MPAS received CE mark approval in February for the treatment of functional mitral regurgitation (FMR).